



GENETIC TOXICOLOGY

FOR PHARMACEUTICALS, MEDICAL DEVICES,
COSMETICS, INDUSTRIAL CHEMICALS:
CHOOSING THE RIGHT TESTING STRATEGY





3 MAIN AREAS IN GENOTOXICITY TESTING:

Gene Mutations

- AMES (OECD 471)
- Mouse Lymphoma Assay (OECD 490)
- HPRT Test (OECD 476)

Chromosome Aberration or Breakage (Clastogenicity)

- Chromosome Aberration Test (OECD 473, 475)

Chromosome Loss or Gain (Aneuploidy)

- Micronucleus Assay (OECD 478, 474)




POSSIBLE FOLLOW-UP EVALUATIONS (IN CASE OF POSITIVE RESULTS):

- *in vivo* Micronucleus Test (OECD 474)
- *in vivo* Chromosome Aberration Test (OECD 475)
- *in vivo* Comet Assay (OECD 489)
- Combination of Micronucleus Test with Comet Assay (OECD 474 + 489)
- Comet with 3D-reconstructed human Skin Model
- Micronucleus Test with 3D-reconstructed human Skin Model

*All *in vivo* assays are performed by our partner lab




PHARMACEUTICALS: TESTING STRATEGY






DECISION TREE FOR IMPURITY ASSESSMENT IN PHARMACEUTICALS





MEDICAL DEVICES: TESTING STRATEGY



Test Battery ISO 10993-3


CA: Chromosome Aberration Test

MLA: Mouse-Lymphoma Assay

MNT: Micronucleus Test



COSMETICS: TESTING STRATEGY



In any case, a weight of evidence approach has to be considered if the previous strategy does not lead to a clear answer. A positive *in vitro* result in genotoxicity testing is indicative for the carcinogenic potential of substances.



INDUSTRIAL CHEMICALS: TESTING STRATEGY

Annex VII: 1– 10 t/a

No further
testing

negative

AMES
or if not possible
MLA/HPRT

positive

Annex VIII: 100– 100 t/a

Annex VII Tests

negative

CA or MN *in vitro*

negative

negative


No further
testing

MLA/HPRT

positive

Annex IX: 100 – 1000 t/a

positive





OUR TESTING OFFER: GENETIC TOXICOLOGY SERVICES

Chromosome Damage

in vitro

- Micronucleus Assay – OECD 487
 - Chinese Hamster Cells
- Human Lymphocytes
- Chromosome Aberration Test – OECD 473
 - Chinese Hamster Cells
 - Human Lymphocytes
- 3D Skin Model combined with Micronucleus Assay – *EpiDerm® Model*

*in vivo**

- Micronucleus Assay (rat or mouse) – OECD 474
 - Peripheral Blood
 - Bone Marrow
- Chromosome Aberration Test – OECD 475
 - Bone Marrow

Gene Mutation

- Ames Test – OECD 471
- Mouse Lymphoma Assay – OECD 490
- HPRT Test – OECD 476
- Pig-a Assay

DNA Strand Breaking Properties

- Comet Assay – OECD 486
 - *in vitro*: (e.g. Chinese Hamster Cells): sponsor specific assay establishment
 - *in vivo**: Stomach, Gut, Liver, Spleen, Kidney: sponsor specific assay establishment
- Combination of Micronucleus Assay and Comet Assay
- 3D Skin Model combined with Comet Assay – *Phenion® model*

Additional Tests

- Embryonic Stem Cell Test
- Drug Uptake *in vitro*
- Hepatocyte Proliferation Assay *in vitro*
 - mouse, rat, human

*All *in vivo* assays are performed by our partner lab



WHY CHOOSE EUROFINS?

- ✓ Our familiarity with an array of different in vitro test systems enables us to provide contract testing services using the optimum assays to answer specific product safety and efficacy questions.
- ✓ In addition to standard testing, we offer consultation concerning your specific project with regard to scientific and regulatory requirements.
- ✓ We will provide you with the most reliable and timely results possible.
- ✓ We offer several standard tests as top priority with outstanding short turnaround time.

With more than 30 years of experience in performing biological safety and activity testing, Eurofins BioPharma Product Testing offers confirmed expertise in a broad range of Genetic & Alternative Toxicology Studies. Our tests comply with the current international guidelines (e.g. ICH, US-FDA, ISO, EMEA, OECD) and are performed in accordance with **GLP (Good Laboratory Practice)** to ensure their acceptability worldwide.





CONTACT US:

+49 (89) 899 650 0

info-munich@eurofins.com

<https://www.eurofins.de/>

Eurofins BioPharma Product Testing Munich GmbH
Behringstr. 6/8
82152 Munich